Remove 2022 Remove Leads Remove Pharmacology
article thumbnail

Injection could help postpartum depression, says study

European Pharmaceutical Review

Most ISRs were mild to moderate in severity and none lead to premature discontinuation from the study. There were no life threatening TEAEs, TEAEs leading to premature discontinuation of study, serious adverse events (SAEs) or deaths. PPD is an extremely common psychological condition affecting women after labour.

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies. Pain and Therapy.

Medicine 102
article thumbnail

NICE to update endometriosis guidelines to improve diagnosis and surgical management

Pharmaceutical Technology

This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life. As a result, women wait eight years on average for a diagnosis after initial symptom onset, a figure that has not changed in a decade.

article thumbnail

Handling HPAPIs safely – what does it take?

European Pharmaceutical Review

1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. internet] GlobeNewswire. Research and Markets. cited 2023Feb].

Safety 98
article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. A 2022 study from the Royal College of Physicians and British Pharmacological Society demonstrated the potential of pharmacogenomics, with scientists identifying the genetic cause behind an individual’s drug response for over forty medicines.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion in 2022 to $4.1 percent between 2022 and 2032. percent between 2022 and 2032. GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. percent from $3.2 billion in 2032. million in sales by 2032.

article thumbnail

Angion stock falls after agreeing Elicio Therapeutics merger

pharmaphorum

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.